Merck-Serono Takes Over Atacicept Development In Partnership Restructuring

ZymoGenetics will save $260 million over four years by converting its co-development deal to a royalty license.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet